578 related articles for article (PubMed ID: 20959606)
61. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
62. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
63. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
[TBL] [Abstract][Full Text] [Related]
64. Targeting nonclassical oncogenes for therapy in T-ALL.
Subramaniam PS; Whye DW; Efimenko E; Chen J; Tosello V; De Keersmaecker K; Kashishian A; Thompson MA; Castillo M; Cordon-Cardo C; Davé UP; Ferrando A; Lannutti BJ; Diacovo TG
Cancer Cell; 2012 Apr; 21(4):459-72. PubMed ID: 22516257
[TBL] [Abstract][Full Text] [Related]
65. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.
Ramadani F; Bolland DJ; Garcon F; Emery JL; Vanhaesebroeck B; Corcoran AE; Okkenhaug K
Sci Signal; 2010 Aug; 3(134):ra60. PubMed ID: 20699475
[TBL] [Abstract][Full Text] [Related]
66. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
67. Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis.
Horak F; Puri KD; Steiner BH; Holes L; Xing G; Zieglmayer P; Zieglmayer R; Lemell P; Yu A
J Allergy Clin Immunol; 2016 Jun; 137(6):1733-1741. PubMed ID: 26915677
[TBL] [Abstract][Full Text] [Related]
68. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
[TBL] [Abstract][Full Text] [Related]
69. Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
Zhang TT; Okkenhaug K; Nashed BF; Puri KD; Knight ZA; Shokat KM; Vanhaesebroeck B; Marshall AJ
J Allergy Clin Immunol; 2008 Oct; 122(4):811-819.e2. PubMed ID: 19014771
[TBL] [Abstract][Full Text] [Related]
70. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
Pitt SC; Chen H; Kunnimalaiyaan M
J Am Coll Surg; 2009 Jul; 209(1):82-8. PubMed ID: 19651067
[TBL] [Abstract][Full Text] [Related]
71. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
Xie C; He Y; Zhen M; Wang Y; Xu Y; Lou L
Cancer Sci; 2017 Jul; 108(7):1476-1484. PubMed ID: 28418085
[TBL] [Abstract][Full Text] [Related]
72. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Evangelisti C; Cappellini A; Oliveira M; Fragoso R; Barata JT; Bertaina A; Locatelli F; Simioni C; Neri LM; Chiarini F; Lonetti A; Buontempo F; Orsini E; Pession A; Manzoli L; Martelli AM; Evangelisti C
J Cell Physiol; 2018 Mar; 233(3):1796-1811. PubMed ID: 28777460
[TBL] [Abstract][Full Text] [Related]
73. Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma.
Rascoe PA; Cao X; Daniel JC; Miller SD; Smythe WR
J Thorac Cardiovasc Surg; 2005 Aug; 130(2):393-400. PubMed ID: 16077404
[TBL] [Abstract][Full Text] [Related]
74. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.
Puri KD; Gold MR
Front Immunol; 2012; 3():256. PubMed ID: 22936933
[TBL] [Abstract][Full Text] [Related]
75. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
76. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
[TBL] [Abstract][Full Text] [Related]
77. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
[TBL] [Abstract][Full Text] [Related]
78. Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ.
Hassenrück F; Farina-Morillas M; Neumann L; Landini F; Blakemore SJ; Rabipour M; Alvarez-Idaboy JR; Pallasch CP; Hallek M; Rebollido-Rios R; Krause G
Commun Biol; 2023 Jun; 6(1):603. PubMed ID: 37277510
[TBL] [Abstract][Full Text] [Related]
79. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.
Williams O; Houseman BT; Kunkel EJ; Aizenstein B; Hoffman R; Knight ZA; Shokat KM
Chem Biol; 2010 Feb; 17(2):123-34. PubMed ID: 20189103
[TBL] [Abstract][Full Text] [Related]
80. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Ali K; Soond DR; Pineiro R; Hagemann T; Pearce W; Lim EL; Bouabe H; Scudamore CL; Hancox T; Maecker H; Friedman L; Turner M; Okkenhaug K; Vanhaesebroeck B
Nature; 2014 Jun; 510(7505):407-411. PubMed ID: 24919154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]